MRI Interventions Changes Corporate Name to ClearPoint Neuro, Inc.

Client Type: Public Company

We are pleased to have advised MRI Interventions, Inc. (Nasdaq: MRIC) in its corporate name change to ClearPoint Neuro, Inc. As part of the name change, ClearPoint Neuro rang the Closing Bell of the Nasdaq Stock Market, and has commenced trading under the symbol “CLPT” as of February 14, 2020. The new name represents the Company’s vision and strategic focus as the medical device extension of its biologics and drug delivery partners.

The team was led by Bass, Berry & Sims corporate attorney Richard Mattern and included corporate attorneys Kristin Dunavant, Taylor Wirth and Whitney Robinson

“We are honored to celebrate with the ClearPoint Neuro team during this important milestone in the Company’s history. Having worked with the team for 14 years, this reflects the Company’s commitment to treating the most complex neurological disorders,” said Richard Mattern. Richard also noted, “We are grateful for the opportunity be a part of ClearPoint Neuro’s growth and look forward to partnering with the management team in the expansion of its neurological product and service offerings.”

To read full press release issued by ClearPoint Neuro (Nasdaq: CLPY), click here.

The Bass, Berry & Sims corporate and securities practice encompasses mergers and acquisitions, capital markets transactions, corporate governance and shareholder activism. We serve as primary corporate and securities counsel to more than 35 public companies and have counseled on 150 deals ranging in size from $20 million to more than $15 billion over the past two years. The team and our attorneys have been consistently recognized in leading industry outlets, including Chambers USA – ranked as a top corporate firm in Tennessee since 2003 – and M&A Advisor Award recipient for “Healthcare & Life Sciences Deal of the Year ($100MM-$1B)” and “Industrials Deal of the Year (Over $1B)” in 2019; “M&A Deal of the Year ($10MM-$25MM” and “Healthcare and Life Sciences Deal of the Year (Over $100MM-$1B)” in 2018; and “M&A Deal of the Year (From $1B-$5B)” and “Corporate/Strategic Deal of the Year (Over $1B)” in 2017.

We are pleased to have advised MRI Interventions, Inc. (Nasdaq: MRIC) in its corporate name change to ClearPoint Neuro, Inc. As part of the name change, ClearPoint Neuro rang the Closing Bell of the Nasdaq Stock Market, and has commenced trading under the symbol “CLPT” as of February 14, 2020. The new name represents the Company’s vision and strategic focus as the medical device extension of its biologics and drug delivery partners.

The team was led by Bass, Berry & Sims corporate attorney Richard Mattern and included corporate attorneys Kristin Dunavant, Taylor Wirth and Whitney Robinson

“We are honored to celebrate with the ClearPoint Neuro team during this important milestone in the Company’s history. Having worked with the team for 14 years, this reflects the Company’s commitment to treating the most complex neurological disorders,” said Richard Mattern. Richard also noted, “We are grateful for the opportunity be a part of ClearPoint Neuro’s growth and look forward to partnering with the management team in the expansion of its neurological product and service offerings.”

To read full press release issued by ClearPoint Neuro (Nasdaq: CLPY), click here.

The Bass, Berry & Sims corporate and securities practice encompasses mergers and acquisitions, capital markets transactions, corporate governance and shareholder activism. We serve as primary corporate and securities counsel to more than 35 public companies and have counseled on 150 deals ranging in size from $20 million to more than $15 billion over the past two years. The team and our attorneys have been consistently recognized in leading industry outlets, including Chambers USA – ranked as a top corporate firm in Tennessee since 2003 – and M&A Advisor Award recipient for “Healthcare & Life Sciences Deal of the Year ($100MM-$1B)” and “Industrials Deal of the Year (Over $1B)” in 2019; “M&A Deal of the Year ($10MM-$25MM” and “Healthcare and Life Sciences Deal of the Year (Over $100MM-$1B)” in 2018; and “M&A Deal of the Year (From $1B-$5B)” and “Corporate/Strategic Deal of the Year (Over $1B)” in 2017.